794 related articles for article (PubMed ID: 33931919)
1. CIRCULATE-Japan: Circulating tumor DNA-guided adaptive platform trials to refine adjuvant therapy for colorectal cancer.
Taniguchi H; Nakamura Y; Kotani D; Yukami H; Mishima S; Sawada K; Shirasu H; Ebi H; Yamanaka T; Aleshin A; Billings PR; Rabinowitz M; Oki E; Takemasa I; Kato T; Mori M; Yoshino T
Cancer Sci; 2021 Jul; 112(7):2915-2920. PubMed ID: 33931919
[TBL] [Abstract][Full Text] [Related]
2. Circulating tumor DNA guided adjuvant chemotherapy in stage II colon cancer (MEDOCC-CrEATE): study protocol for a trial within a cohort study.
Schraa SJ; van Rooijen KL; van der Kruijssen DEW; Rubio Alarcón C; Phallen J; Sausen M; Simmons J; Coupé VMH; van Grevenstein WMU; Elias S; Verkooijen HM; Laclé MM; Bosch LJW; van den Broek D; Meijer GA; Velculescu VE; Fijneman RJA; Vink GR; Koopman M;
BMC Cancer; 2020 Aug; 20(1):790. PubMed ID: 32819390
[TBL] [Abstract][Full Text] [Related]
3. Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer.
Tie J; Cohen JD; Lahouel K; Lo SN; Wang Y; Kosmider S; Wong R; Shapiro J; Lee M; Harris S; Khattak A; Burge M; Harris M; Lynam J; Nott L; Day F; Hayes T; McLachlan SA; Lee B; Ptak J; Silliman N; Dobbyn L; Popoli M; Hruban R; Lennon AM; Papadopoulos N; Kinzler KW; Vogelstein B; Tomasetti C; Gibbs P;
N Engl J Med; 2022 Jun; 386(24):2261-2272. PubMed ID: 35657320
[TBL] [Abstract][Full Text] [Related]
4. The CIRCULATE Trial: Circulating Tumor DNA Based Decision for Adjuvant Treatment in Colon Cancer Stage II Evaluation (AIO-KRK-0217).
Folprecht G; Reinacher-Schick A; Weitz J; Lugnier C; Kraeft AL; Wisser S; Aust DE; Weiss L; von Bubnoff N; Kramer M; Thiede C; Tannapfel A
Clin Colorectal Cancer; 2022 Jun; 21(2):170-174. PubMed ID: 34772609
[TBL] [Abstract][Full Text] [Related]
5. Minimal Residual Disease-Directed Adjuvant Therapy for Patients With Early-Stage Colon Cancer: CIRCULATE-US.
Sahin IH; Lin Y; Yothers G; Lucas PC; Deming D; George TJ; Kopetz S; Lieu CH; Dasari A
Oncology (Williston Park); 2022 Oct; 36(10):604-608. PubMed ID: 36260786
[TBL] [Abstract][Full Text] [Related]
6. Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study.
Tie J; Wang Y; Cohen J; Li L; Hong W; Christie M; Wong HL; Kosmider S; Wong R; Thomson B; Choi J; Fox A; Field K; Burge M; Shannon J; Kotasek D; Tebbutt NC; Karapetis C; Underhill C; Haydon A; Schaeffer J; Ptak J; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
PLoS Med; 2021 May; 18(5):e1003620. PubMed ID: 33939694
[TBL] [Abstract][Full Text] [Related]
7. Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer.
Tie J; Cohen JD; Wang Y; Christie M; Simons K; Lee M; Wong R; Kosmider S; Ananda S; McKendrick J; Lee B; Cho JH; Faragher I; Jones IT; Ptak J; Schaeffer MJ; Silliman N; Dobbyn L; Li L; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
JAMA Oncol; 2019 Dec; 5(12):1710-1717. PubMed ID: 31621801
[TBL] [Abstract][Full Text] [Related]
8. Dynamic monitoring of circulating tumor DNA to predict prognosis and efficacy of adjuvant chemotherapy after resection of colorectal liver metastases.
Wang DS; Yang H; Liu XY; Chen ZG; Wang Y; Fong WP; Hu MT; Zheng YC; Zheng Y; Li BK; Yuan YF; Chen G; Pan ZZ; Song L; Li YH; Xu RH
Theranostics; 2021; 11(14):7018-7028. PubMed ID: 34093868
[No Abstract] [Full Text] [Related]
9. Molecular Residual Disease-guided Adjuvant Treatment in Resected Colorectal Cancer: Focus on CIRCULATE-Japan.
Sato S; Nakamura Y; Oki E; Yoshino T
Clin Colorectal Cancer; 2023 Mar; 22(1):53-58. PubMed ID: 36567192
[TBL] [Abstract][Full Text] [Related]
10. Circulating Tumor DNA as a Minimal Residual Disease Assessment and Recurrence Risk in Patients Undergoing Curative-Intent Resection with or without Adjuvant Chemotherapy in Colorectal Cancer: A Systematic Review and Meta-Analysis.
Chidharla A; Rapoport E; Agarwal K; Madala S; Linares B; Sun W; Chakrabarti S; Kasi A
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373376
[TBL] [Abstract][Full Text] [Related]
11. Circulating tumor DNA is a prognostic marker of tumor recurrence in stage II and III colorectal cancer: multicentric, prospective cohort study (ALGECOLS).
Benhaim L; Bouché O; Normand C; Didelot A; Mulot C; Le Corre D; Garrigou S; Djadi-Prat J; Wang-Renault SF; Perez-Toralla K; Pekin D; Poulet G; Landi B; Taieb J; Selvy M; Emile JF; Lecomte T; Blons H; Chatellier G; Link DR; Taly V; Laurent-Puig P
Eur J Cancer; 2021 Dec; 159():24-33. PubMed ID: 34731746
[TBL] [Abstract][Full Text] [Related]
12. Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial.
Petrelli F; Labianca R; Zaniboni A; Lonardi S; Galli F; Rulli E; Rosati G; Corallo S; Ronzoni M; Cardellino GG; Mattioli R; Mambrini A; Ciuffreda L; Banzi M; Pusceddu V; Maiello E; Zampino M; Zagonel V; Marchetti P; Corsi D; Rimassa L; Cinieri S; Sobrero A
JAMA Oncol; 2020 Apr; 6(4):547-551. PubMed ID: 32053133
[TBL] [Abstract][Full Text] [Related]
13. ctDNA guided adjuvant chemotherapy versus standard of care adjuvant chemotherapy after curative surgery in patients with high risk stage II or stage III colorectal cancer: a multi-centre, prospective, randomised control trial (TRACC Part C).
Slater S; Bryant A; Chen HC; Begum R; Rana I; Aresu M; Peckitt C; Zhitkov O; Lazaro-Alcausi R; Borja V; Powell R; Lowery D; Hubank M; Rich T; Anandappa G; Chau I; Starling N; Cunningham D
BMC Cancer; 2023 Mar; 23(1):257. PubMed ID: 36941575
[TBL] [Abstract][Full Text] [Related]
14. Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer.
Lee B; Lipton L; Cohen J; Tie J; Javed AA; Li L; Goldstein D; Burge M; Cooray P; Nagrial A; Tebbutt NC; Thomson B; Nikfarjam M; Harris M; Haydon A; Lawrence B; Tai DWM; Simons K; Lennon AM; Wolfgang CL; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
Ann Oncol; 2019 Sep; 30(9):1472-1478. PubMed ID: 31250894
[TBL] [Abstract][Full Text] [Related]
15. "Decision for adjuvant treatment in stage II colon cancer based on circulating tumor DNA:The CIRCULATE-PRODIGE 70 trial".
Taïeb J; Benhaim L; Laurent Puig P; Le Malicot K; Emile JF; Geillon F; Tougeron D; Manfredi S; Chauvenet M; Taly V; Lepage C; André T
Dig Liver Dis; 2020 Jul; 52(7):730-733. PubMed ID: 32482534
[TBL] [Abstract][Full Text] [Related]
16. Circulating Tumour DNA and Colorectal Cancer: the Next Revolutionary Biomarker?
Naidoo M; Piercey O; Tie J
Curr Oncol Rep; 2021 Nov; 23(12):140. PubMed ID: 34735665
[TBL] [Abstract][Full Text] [Related]
17. Circulating tumour DNA as a biomarker in resectable and irresectable stage IV colorectal cancer; a systematic review and meta-analysis.
Jones RP; Pugh SA; Graham J; Primrose JN; Barriuso J
Eur J Cancer; 2021 Feb; 144():368-381. PubMed ID: 33422803
[TBL] [Abstract][Full Text] [Related]
18. Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer.
Chen G; Peng J; Xiao Q; Wu HX; Wu X; Wang F; Li L; Ding P; Zhao Q; Li Y; Wang D; Shao Y; Bao H; Pan Z; Ding KF; Cai S; Wang F; Xu RH
J Hematol Oncol; 2021 May; 14(1):80. PubMed ID: 34001194
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Value and Relation with Adjuvant Treatment Duration of ctDNA in Stage III Colon Cancer: a
Taieb J; Taly V; Henriques J; Bourreau C; Mineur L; Bennouna J; Desrame J; Louvet C; Lepere C; Mabro M; Egreteau J; Bouche O; Mulot C; Hormigos K; Chaba K; Mazard T; de Gramont A; Vernerey D; André T; Laurent-Puig P
Clin Cancer Res; 2021 Oct; 27(20):5638-5646. PubMed ID: 34083233
[TBL] [Abstract][Full Text] [Related]
20. Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer.
Kotani D; Oki E; Nakamura Y; Yukami H; Mishima S; Bando H; Shirasu H; Yamazaki K; Watanabe J; Kotaka M; Hirata K; Akazawa N; Kataoka K; Sharma S; Aushev VN; Aleshin A; Misumi T; Taniguchi H; Takemasa I; Kato T; Mori M; Yoshino T
Nat Med; 2023 Jan; 29(1):127-134. PubMed ID: 36646802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
